



# Conference attendance

January 27, 2022

RNS Number : 7789Z

Renalytix PLC

27 January 2022

## **Renalytix plc ("Renalytix" or the "Company")**

### **Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference**

**New York and SALT LAKE CITY, January 27, 2022** - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Renalytix's management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available for virtual 1X1 meetings with investors registered for the event.

### **About Renalytix**

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit [www.kidneyintelx.com](http://www.kidneyintelx.com)). For more information, visit [www.renalytix.com](http://www.renalytix.com).

### ***For further information, please contact:***

#### **Renalytix plc**

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

**Via Walbrook PR**

#### **Stifel (Nominated Adviser, Joint Broker)**

Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

#### **Investec Bank plc (Joint Broker)**

**Tel: 020 7597 4000**

Gary Clarence / Daniel Adams

**Walbrook PR Limited**

Paul McManus / Lianne Applegarth

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07584 391 303

**CapComm Partners**

Peter DeNardo

**Tel: 415-389-6400** or

[investors@renalytix.com](mailto:investors@renalytix.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFIFILFIDFIF